• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Genetic risk assessment for Alzheimer’s disease does not increase anxiety, depression or stress

byKenan Celtik, MSandSai Folmsbee
January 26, 2016
in Cardiology, Public Health
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. From a randomized trial, the disclosure of genetic risk information to those with increased risk of Alzheimer’s disease and coronary artery disease did not increase their anxiety or depression.

2. Disclosing genetic risk information was associated with positive lifestyle modifications, particularly in those who received information about coronary artery disease risk.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Genome sequencing has become more common in all medical specialties, yet the psychological and behavioral impact of disclosing disease risk information to patients has not been thoroughly studied. A variant of the apolipoprotein E, APOE gene, has been shown to confer an increased risk of Alzheimer’s disease (AD) and, to a lesser degree, coronary artery disease (CAD). Therefore, this trial sought to determine if disclosing disease risk information affected psychological health or led patients to make beneficial lifestyle modifications. Participants were randomized to receive risk information about only AD or both AD and CAD (AD+CAD), prior to having their blood drawn for genomic analysis. More than half of all participants changed a health behavior in response to their genetic risk information, and nearly one quarter of participants reported moderate anxiety, depression or test-related distress at ≥1 point in the study with no difference between groups. APOE risk carriers who received risk information about AD had higher mean test-related distress and anxiety scores than non-carriers, but there was no difference in mean depression scores. The receipt of AD+CAD information was associated with lower mean anxiety in carriers, but increased mean anxiety in noncarriers. Interestingly, the AD+CAD group was more likely to report lifestyle changes. The primary limitation of this study was that lifestyle modification changes were self-reported. Overall, these data indicate that genetic risk assessments likely will not negatively impact their patients’ psychological wellbeing.

Click to read the study published today in the Annals of Internal Medicine

Relevant Reading: Factors Affecting Recall of Different Types of Personal Genetic Information about Alzheimer’s Disease Risk: The REVEAL Study

RELATED REPORTS

Patients with coronary artery disease have sustained elevation in blood pressure following exercise

Genome classifiers may aid prostate cancer risk stratification and treatment

The Scan by 2 Minute Medicine®: Versatile Ozempic, Healthcare Reform, Unlocking the Brain, and Chickens and the Next Pandemic:

In-Depth [randomized controlled trial]: In this study, 290 patients from four institutions were randomly assigned to receive risk information for AD only (n = 156) or both AD and CAD (n = 140). After randomization, patients met with genetic counselors to have their blood drawn, determine their family history of AD and establish baseline anxiety and depression. At no point did any participant meet thresholds for mood disorders. The primary endpoint was test-related distress, depression and anxiety were measured using validated questionnaires at 12 months. Patients with more than 1 first degree relative with AD and those with mood disorders at baseline were excluded. Test-related stress, depression and anxiety were measured using the Impact Event Scale (IES), Center for Epidemiologic Studies Depression Scale (CES-D) and Beck Anxiety Inventory (BAI), respectively. At 12 months, the mean BAI was 3.5 and 3.5 for AD-only and AD+CAD, respectively (difference 0.0; 95%CI -1.0 to 1.0), whereas mean CES-D was 6.4 and 7.1 for AD and AD+CAD, respectively (difference 0.7; 95%CI -1.0 to 2.4). CES-D >11 indicates mild depression and BAI >9 indicates mild anxiety. Mean IES was 4.0 and 2.6 for AD and AD+CAD, respectively (difference -1.4; 95%CI -3.3 to 0.5). IES ≥20 indicates significant distress.

Image: CC/Wiki

©2016 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: Alzheimer’s diseaseCoronary artery diseasegenetic testing
Previous Post

Annual fecal immunochemical test screening associated with high sensitivity for colorectal cancer

Next Post

CT of the chest, abdomen, and pelvis demonstrates low diagnostic yield in low-velocity trauma

RelatedReports

Prevalence of hypertension among adolescents varies by race and BMI
Cardiology

Patients with coronary artery disease have sustained elevation in blood pressure following exercise

February 28, 2025
BRAF V600E mutations linked with increased mortality in thyroid cancer
Oncology

Genome classifiers may aid prostate cancer risk stratification and treatment

January 20, 2025
The Scan by 2 Minute Medicine®:  Ultra-Trail du Mont-Blanc, Taylor Swift, NBA rookie Chet Holmgren and Magic Mushrooms!
The Scan by 2 Minute Medicine®

The Scan by 2 Minute Medicine®: Versatile Ozempic, Healthcare Reform, Unlocking the Brain, and Chickens and the Next Pandemic:

January 7, 2025
Public Health

Caregivers of people with dementia may benefit from online decision aid when managing firearm access

October 22, 2024
Next Post
Computed tomography improves diagnostic certainty in the emergency department

CT of the chest, abdomen, and pelvis demonstrates low diagnostic yield in low-velocity trauma

Smoking during pregnancy associated with aerobic fitness of children

Smoking cessation rates equivalent between most common pharmacotherapies

USPSTF finds insufficient evidence for screening for iron deficiency anemia during pregnancy

Prenatal vitamin D supplementation does not reduce incidence of asthma

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Cerebral embolic protection does not decrease stroke incidence in TAVI patients
  • Nerandomilast slows FVC decline in progressive pulmonary fibrosis
  • 2 Minute Medicine: Pharma Roundup – Gastric Immunotherapy Gains, Prostate Pill Expansion, Five-Minute Myeloma Dosing, and Streamlined CAR-T Access [July 8th 2025]
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.